RSS   Newsletter   Contact   Advertise with us
Post Online Media

Akcea Therapeutics appoints three to board

Akcea TherapeuticsAkcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, announced three additions to the company's board of directors.

Christopher Gabrieli, partner emeritus of Bessemer Venture Partners, will serve as chairman of the board of Akcea Therapeutics.

Mr. Gabrieli a partner emeritus at Bessemer Venture Partners, a venture capital fund.

Previously, as a partner at Bessemer, Mr. Gabrieli led their life sciences practice and made a founding investment in Ionis Pharmaceuticals.

Mr. Gabrieli is also the chairman of the Massachusetts Board of Higher Education and a part-time lecturer at the Harvard Graduate School of Education.

Elaine Hochberg is a managing partner of Elaran, LLC, a business strategy and management firm.

Ms. Hochberg has held a number of commercial leadership positions at both Forest Laboratories and Wyeth-Ayerst Laboratories.

At Forest, Ms. Hochberg served as chief commercial officer, executive vice president, international, strategic planning and government affairs and senior vice president-marketing.

Ms. Hochberg has led the buildout of significant product portfolios and brand franchises spanning a broad array of therapeutic areas in both the U.S. and international markets.

She has launched more than thirty products.

Sandford D. Smith has, for the past 20 years, focused on drugs and therapies for rare genetic diseases.

Mr. Smith has served as founder and chairman of Global Biolink Partners, Aegerion's interim chief executive officer, and following Aegerion's merger with Novelion, he serves as Novelion's vice chair.

Mr. Smith held various positions at Sanofi-Genzyme (formerly Genzyme Corporation), most recently leading the integration of Genzyme's international business into Sanofi's global organization and, prior to that, he served as executive vice president of Genzyme Corporation, and president of Genzyme International.

Mr. Smith was president, chief executive officer and a member of the board of directors of RepliGen Corporation.

He also held various positions at Bristol-Myers Squibb, most recently as vice president of business development and strategic planning for the pharmaceutical and nutritional division.

Mr. Smith currently serves on the boards of Cytokinetics Inc., Apricus Biosciences and Neuralstem.


 LATEST MOVES FROM Massachusetts 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy